Sun 29 Jun 2008
Its been a struggle for the Indian biotechnology industry for many years now. They are questioned on their product quality by atleast four authorities starting from the health ministry to the environment ministry.
But there is some hope that could end their plight. As P T Jyothi Datta of Hindu Business Line reports, one apex authority called the National Biotechnology Regulatory Authority, could be the single stop window for clearance of future recombinant and gene therapy products.
That may not essentially include products like insulin or hepatitis B products whose active ingredients are derived from GMOs but may not be living GMOs themselves. Here is an interesting report.